Cancer clinical development strategy

Oncology Scientific Advisory Board An emerging drug discovery company, with a core expertise in molecular modelling, had developed a small molecule inhibitor of a novel cancer metabolism target. The...
Learn More

Transatlantic payer research - pain therapy

A pharmaceutical company asked Alacrita to assist in providing an HTA/payer perspective on the proposed label and mechanism of action/clinical positioning for its pain drug, to ensure that the Phase...
Learn More

EU payer research to inform Phase 3 design

A Cambridge MA based therapeutics company asked Alacrita to provide feedback on the Phase III protocol design for its lead drug, specifically from an EU payer perspective. Alacrita’s expert European...
Learn More

Feasibility study - ophthalmic therapies

A leading research institute developing novel approaches for production of ophthalmic treatments asked Alacrita to conduct a market and competitive assessment of the current supplier base and...
Learn More

Medical device technology assessment

A university research team had worked for a number of years on the development of a novel interventional cardiology device. Recent progress had been made with pre-clinical testing on pigs, as well as...
Learn More

Supporting due diligence on regulatory affairs

Challenge: A clinical stage biopharmaceutical specialist needed support with its regulatory due diligence activities for products in the respiratory field.
Learn More

Payer research and pricing assessment

Alacrita was asked to assess the market opportunity for a novel anaemia therapy in order to facilitate discussions with potential partners. Alacrita conducted the assessment in two stages.
Learn More

Opportunity analysis - blood products

A life science venture capital fund was contemplating investing in advanced plasma product opportunities being developed by a biopharmaceutical company. Alacrita was commissioned to provide a reality...
Learn More

Wound care - regulatory support

10111A world-leading manufacturer of wound care products was assessing opportunities in advanced wound care, and has mapped regulatory pathways that pertained to various classes of product. Having...
Learn More

GMP facility - feasibility study for biologics production

Drawing on expertise from its regulatory, gene therapy and manufacturing consultants, Alacrita conducted feasibility study and formulated a business case for a new GMP facility for production of...
Learn More

Valuation and Deal Support

Oncology company with a preclinical project seeking finance and potential acquisition For a virtual life science company, Alacrita helped establish a valuation trajectory for one of their products,...
Learn More

Designing and monitoring anti-NGF antibody imaging endpoints

Challenge: Anti-nerve growth factor inhibitors are a new class of powerful analgesics in clinical development. They were put on clinical development hold by the FDA in 2012 due to joint-related...
Learn More
Previous
1 ... 25 26 27 28 29
Next

Need biotech consulting support? We can help.

Contact us today to learn how our pharma & biotech consulting expertise can serve your project.

Contact us

Explore our biotech & life science consulting services

© 2023 Alacrita Holdings Limited  |   Pharma & Biotech Consulting

Alacrita Consulting 
2 Royal College St
London, UK
NW1 0NH

Registered in England & Wales.
No. 10530608


One Broadway
Floor 14
Cambridge, MA 02142

Registered in Massachusetts.